Exelixis

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Exelixis, Inc. (EXEL) stock price, news, quote and history (öffnet in neuem Tab)

  Yahoo Finance UK · 02.10.2026

• Exelixis, Inc. Podcast | EXEL Podcasts & Related Content (öffnet in neuem Tab)

  finance.biggo.com · 01.10.2026

• Exelixis, Inc. (EXEL) Stock Price, News, Quote & History (öffnet in neuem Tab)

  Yahoo! Finance Canada · 01.10.2026

• (EXEL) Volatility Zones as Tactical Triggers (öffnet in neuem Tab)

  Stock Traders Daily · 01.10.2026

• Exelixis Shares Rising on CABOMETYX Revenue (öffnet in neuem Tab)

  Yahoo Finance · 30.09.2026

• Exelixis stock hits all-time high at 59.73 USD By Investing.com (öffnet in neuem Tab)

  Investing.com UK · 30.09.2026

• Return on equity % of Exelixis, Inc. – HAN:EX9 (öffnet in neuem Tab)

  TradingView · 30.09.2026

• How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension (öffnet in neuem Tab)

  webull.com · 25.09.2026

• Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? (öffnet in neuem Tab)

  Yahoo Finance · 24.09.2026

• Exelixis, Inc. (EXEL) Stock Forecasts (öffnet in neuem Tab)

  Yahoo! Finance Canada · 24.09.2026

• Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer (öffnet in neuem Tab)

  Yahoo Finance · 21.09.2026

• Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B (öffnet in neuem Tab)

  Yahoo Finance · 17.09.2026

• Can Exelixis (EXEL) Stay Cheap After A 185% Five Year Run? (öffnet in neuem Tab)

  Simply Wall Street · 17.09.2026

• Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? (öffnet in neuem Tab)

  Yahoo Finance · 16.09.2026

• Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle (öffnet in neuem Tab)

  Yahoo Finance · 15.09.2026

• Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML) (öffnet in neuem Tab)

  The Globe and Mail · 15.09.2026

• Exelixis: The FDA Delay Costs Less Than The Market Thinks (NASDAQ:EXEL) (öffnet in neuem Tab)

  Seeking Alpha · 14.09.2026

• Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises (öffnet in neuem Tab)

  Yahoo Finance · 14.09.2026

• FDA delays review of Exelixis' zanzalintinib by 3 months, no new safety issues found (öffnet in neuem Tab)

  Pluang · 14.09.2026

• Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade) (öffnet in neuem Tab)

  Seeking Alpha · 14.09.2026

• Exelixis (EXEL) Gets Longer FDA Review As Cancer Pipeline Milestone Advances (öffnet in neuem Tab)

  Simply Wall Street · 12.09.2026

• FDA extends review of Exelixis drug application for metastatic colorectal cancer (öffnet in neuem Tab)

  Investing.com India · 11.09.2026

• US FDA extends review of Exelixis’ cancer drug (öffnet in neuem Tab)

  WSAU · 11.09.2026

• After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis (öffnet in neuem Tab)

  Fierce Pharma · 11.09.2026

• Exelixis Says FDA Extended Review Period for Colorectal Cancer Drug (öffnet in neuem Tab)

  Yahoo Finance · 11.09.2026

• Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months (öffnet in neuem Tab)

  Yahoo Finance · 11.09.2026

• Exelixis stock falls as FDA extends zanzalintinib review By Investing.com (öffnet in neuem Tab)

  Investing.com UK · 11.09.2026

• Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In (öffnet in neuem Tab)

  Benzinga · 11.09.2026

• EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term (öffnet in neuem Tab)

  Yahoo Finance · 11.09.2026

• FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer (öffnet in neuem Tab)

  Fierce Biotech · 11.09.2026